Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $32.29

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned an average rating of “Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $32.29.

A number of research firms have issued reports on CPRX. Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Bank of America restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $23.23 on Friday. Catalyst Pharmaceuticals has a 52-week low of $14.47 and a 52-week high of $26.16. The company has a fifty day moving average of $22.62 and a 200-day moving average of $22.05. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of 19.69, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $29,000. Farther Finance Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,495 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 579 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $65,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.